Anticipatory nausea in animal models: A review of potential novel therapeutic treatments

Experimental Brain Research

Volumn 232, Issue 8, 2014, Pages 2511-2534

  Rock, Erin M ^a   Limebeer, Cheryl L ^a   Parker, Linda A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Anticipatory; Cannabinoids; Context; Gaping; Nausea; Rat

Indexed keywords

APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABINOID; CANNABINOID DERIVATIVE; CORTICOSTEROID; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; SEROTONIN; SEROTONIN 3 RECEPTOR; SUCROSE; TETRAHYDROCANNABINOLIC ACID; TETRAHYDROCANNABIVARIN; UNCLASSIFIED DRUG; CANNABIDIOLIC ACID; CANNABIDIVARIN; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE INHIBITOR; MAGL INHIBITOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT;

ALTERNATIVE MEDICINE; ANIMAL MODEL; ANTICIPATORY NAUSEA AND VOMITING; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); GINGER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; ANIMAL EXPERIMENT; DRUG THERAPY; ENZYME INHIBITION; ANIMAL; DISEASE MODEL; NAUSEA;

ANIMALS; ANTIEMETICS; DISEASE MODELS, ANIMAL; HUMANS; NAUSEA;

EID: 84905576131     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-014-3942-9     Document Type: Review

References (301)

1. Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21:885-897
2. Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 7:11-14
3. Aapro MS, Kirchner V, Terrey JP (1994) The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 69:957-960
4. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research (2003) A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14:291-297
5. Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117-121
6. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449
7. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088. doi:10.1093/annonc/mdp584
8. Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 39:113-117
9. Aapro-Piacentini M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko IT, Sarosiek C, Oprean S, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol [Epub ahead of print]
10. Addelman M, Erlichman C, Fine S, Warr D, Murray C (1990) Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337-341
11. Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48:657-663
12. Akechi T, Okuyama T, Endo C, Sagawa R et al (2010) Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 101:2596-2600. doi:10.1111/j.1349-7006.2010.01718.x
13. Alba E, Bastus R, de Andres L, Sola C, Paredes A, Lopez Lopez JJ (1999) Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 46:26-30
14. Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, Halverson J, Convy L, Cook L, Mick K et al (1995) Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 17:145-150
15. Andrews PLR, Sanger GJ (2014) Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 722:108-121
16. Andrykowski MA (1990) The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom Med 52:458-475
17. Andrykowski MA, Redd WH (1987) Longitudinal analysis of the development of anticipatory nausea. J Consult Clin Psychol 55:36-41
18. Andrykowski MA, Jacobsen PB, Marks E, Gorfinkle K, Hakes TB, Kaufman RJ, Currie VE, Holland JC, Redd WH (1988) Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607-2613
19. Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, Inoue K, Kuranami M, Mizutani M, Masuda N (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20(7):1507-1514. doi:10.1007/s00520-011-1239-0
20. Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM (2009) Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115:5807-5816. doi:10.1002/cncr.24630
21. Basurto C, Roila F, Bracarda S, Tonato M, Ballatori E, Del Favero A (1988) A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Am J Clin Oncol 11:594-596
22. Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356. doi:10.1016/j.chembiol.2007.11.006
23. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456-1470. doi:10.1111/bph.12043
24. Bovbjerg DH (2006) The continuing problem of post chemotherapy nausea and vomiting: contributions of classical conditioning. Auton Neurosci 129:92-98
25. Bovbjerg DH, Redd WH, Jacobsen PB et al (1992) An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosom Med 54:623-637
26. Broberg DJ, Bernstein IL (1987) Candy as a scapegoat in the prevention of food aversions in children receiving chemotherapy. Cancer 60:2344-2347
27. Brown I, Cascio MG, Rotondo D, Pertwee RG, Heys SD, Wahle KW (2013) Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res 52:80-109. doi:10.1016/j.plipres.2012.10.001
28. Brugnatelli S, Gattoni E, Grasso D, Rossetti F, Perrone T, Danova M (2011) Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 97:362-3666. doi:10.1700/912.10035
29. Bruntsch U, Rüfenacht E, Parker I, Drechsler S, de Bruijn K (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann Oncol 4(Suppl 3):25-29
30. Bruntsch U, Drechsler S, Eggert J, Gosse H, Ukena D, Imhoff W, Faerber L (1994) Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Semin Oncol 21:S7-S11
31. Burish TG, Carey MP (1986) Conditioned aversive responses in cancer chemotherapy patients: theoretical and developmental analysis. J Consult Clin Psychol 54:593-600
32. Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R (1991) Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). Oncology 48:403-405
33. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767
34. Carey MP, Burish TG (1988) Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull 104:307-325
35. Carey MP, Burish TG, Brenner DE (1983) Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99:106-114
36. Casper J, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H (1994) 5-HT3 antagonist ondansetron for the treatment of chemotherapy-induced nausea and vomiting in an outpatient population. Int J Oncol 4:1283-1289
37. Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, Italian Trials in Medical Oncology Group (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225. doi:10.1007/s00520-010-0941-7
38. Cella DF, Pratt A, Holland JC (1986) Persistent anticipatory nausea, vomiting, and anxiety in cured Hodgkin's disease patients after completion of chemotherapy. Am J Psychiatry 143:641-643
39. Chan HSL, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotheraoy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79:946-952
40. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Simon RM, Rosenberg SA (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91:819-824
41. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300
42. Chevallier B, Marty M, Paillarse JM (1994) Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group. Br J Cancer 70:1171-1175
43. Chin SB, Kucuk O, Peterson R, Ezdinli EZ (1992) Variables contributing to anticipatory nausea and vomiting in cancer chemotherapy. Am J Clin Oncol 15:262-267
44. Choi CH, Kim MK, Park JY, Yoon A, Kim HJ, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS (2014) Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer 22:1181-1187. doi10.1007/s00520-013-2070-6
45. Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr, Harwood S, Franklin R, Cohen MH (1985) Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69:109-112
46. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842
47. Cohen RE, Blanchard EB, Ruckdeschel JC, Smolen RC (1986) Prevalence and correlates of posttreatment and anticipatory nausea and vomiting in cancer chemotherapy. J Psychosom Res 30:643-654
48. Cone LA, Greene DS, Helm NA (1982) Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer Treat Rev 9:63-70
49. Contreras M, Ceric F, Torrealba F (2007) Inactivation of the interoceptive insula disrupts drug craving and malaise induced by lithium. Science 318:655-659
50. Coppes MJ, Yanofsky R, Pritchard S, Leclerc JM, Howard DR, Perrotta M, Keays S, Pyesmany A, Dempsey E, Pratt CB (1999) Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 21:274-283
51. Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25:959-961
52. Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3:39-42
53. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J (1981) Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol 21(8-9 Suppl):43S-50S
54. Cunningham D, Turner A, Hawthorn J, Rosin RD (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet 1:1323
55. Dalzell AM, Bartlett H, Lilleyman JS (1986) Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 61:502-505
56. Darmani NA (2001) Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24:198-203
57. Davey VA, Biederman GB (1998) Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. JEP Anim Behav Proc 24:483-491
58. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105-4111
59. deBoer-Dennert M, deWit R, Schmitz I, Djontono J, Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
60. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Woodcock S, Fleming H, Dorward P, Pigliacampo B, Close S, Platt B, Ridel G (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), delta-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology 219:859-873. doi:10.1007/s00213-011-2415-0
61. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
62. Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M (2011) Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 19:1505-1510. doi:10.1007/s00520-010-0974-y
63. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824. doi:10.1073/pnas.152334899
64. Dolgin MJ, Katz ER, McGinty K, Siegel SE (1985) Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 75:547-552
65. Drechsler S, Bruntsch U, Eggert J, Grote-Kiehn J, Gosse H, Bangerter M, Ukena D, Oehm C, Mezger J, Faerber L, Imhoff W, Untch M, Gallmeier WM (1997) Comparison of three tropise-tron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Support Care Cancer 5:387-395
66. Duran M, Perez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70:656-663. doi:10.1111/j.1365-2125.2010.03743.x
67. Eckert RM (2001) Understanding anticipatory nausea. Oncol Nurs Forum 28:1553-1558
68. Einhorn L (1982) Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev 9(Suppl B):55-61
69. Einhorn LH, Nagy C, Furnas B, Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21(8-9 Suppl):64S-69S
70. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293-1300
71. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15:330-337
72. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P (1979) Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9- tetrahydrocannabinol. Med J Aust 2:657-659
73. Fahimi F, Khodadad K, Amini S, Naghibi F, Salamzadeh J, Baniasadi S (2011) Evaluating the effect of zingiber officinalis on nausea and vomiting in patients receiving cisplatin based regimens. Iran J Pharm Res 10:379-384
74. Fauser AA, Pizzocaro G, Schueller J, Khayat D, Wilkinson P (2000) A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 8:49-54
75. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358. doi:10.1124/jpet.104.078980
76. Fernández-Marcos A, Martín M, Sanchez JJ, Rodriguez-Lescure A, Casado A, López Martin JA, Diaz-Rubio E (1996) Acute and anticipatory emesis in breast cancer patients. Support Care Cancer 4:370-377
77. Fetting JH, Wilcox PM, Iwata BA, Criswell EL, Bosmajian LS, Sheidler VR (1983) Anticipatory nausea and vomiting in an ambulatory medical oncology population. Cancer Treat Rep 67:1093-1098
78. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, Ryan JL, Kohli S, Palesh OG, Ryan EP, Carroll J, Morrow GR (2007) Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 5:44-50
79. Foubert J, Vaessen G (2005) Nausea: the neglected symptom? Eur J Oncol Nurs 9:21-32
80. Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, Schutt AJ, Schwarta NW (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91:825-830
81. Gagen M, Gochnour D, Young D, Gaginella T, Neidhart J (1984) A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting. J Clin Oncol 2:696-701
82. Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 43:73-76. doi:10.1111/j.1445-5994.2011.02637.x
83. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
84. Garcia J, Hankins WG, Rusiniak KW (1977a) Behavioral regulation of the milieu interne in man and rat. Science 185:824-831
85. Garcia J, Rusiniak KW, Brett L (1977b) Conditioning food-illness aversions in wild animals: Caveant canonici. In: Davis H, Hurowitz H (eds) Operant Pavlovian interactions. Hillsdale, Erlbaum
86. Garcia-del-Muro X, Vadell C, Pérez Manga G, Bover I, Rifá J, Beltrán M, Barros MM, Germá JR, Fabregat X, Moreno V, Salvador A, Viladiu P (1998) Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer 34:193-195
87. Gill EW, Paton WDM, Pertwee RG (1970) Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228:134-136
88. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 9:661-666
89. Goldschmidt H, Salwender H, Egerer G, Kempe R, Voigt T (1997) Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs 8:436-444
90. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B, Adolescent Aprepitant in Cancer Study Group (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242-247. doi:10.1002/pbc.21811
91. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864-868
92. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(189):195
93. Grill HJ, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143:263-279
94. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethaasone, and aprepitant. J Support Oncol 4:403-408
95. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment - how are we doing? J Support Oncol 2(suppl 1):1-12
96. Grunberg SM (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 18:233-240
97. Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J (2009) Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:549-558. doi:10.1016/S1470-2045(09)70109-3
98. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol - EASE. J Clin Oncol 29:1495-1501. doi:10.1200/JCO.2010.31.7859
99. Grunfeld Y, Edery H (1969) Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 14:200-210
100. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 19:843-851
101. Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA (2006) Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 4:467-471
102. Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A (2007) Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract 13:69-75
103. Harousseau JL, Zittoun R, Bonneterre J, Hedouin M, Ouvry J (2000) Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination. Bull Cancer 87:491-497
104. Heim ME, Romer W, Queisser W (1981) Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J Clin Pharmacol 21(8-9 Suppl):86S-89S
105. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295-1297
106. Hermann H, Marsicano G, Lutz B (2002) Coexpressionof the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Nuroscience 109:451-456
107. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112:2080-2087. doi:10.1002/cncr.23364
108. Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27:5363-5369. doi:10.1200/JCO.2009.21.8511
109. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494
110. Hesketh PJ, Sanz-Altamira P (2012) Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophos-phamide- induced nausea and vomiting. Support Care Cancer 20:653-656. doi:10.1007/s00520-011-1312-8
111. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J Clin Oncol 21:4112-4119
112. Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354-360
113. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla R (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol [Epub ahead of print]
114. Hewitt M, McQuade B, Stevens R (1993) The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol (R Coll Radiol) 5:11-14
115. Hickok JT, Roscoe JA, Morrow GR (2001) The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 22:843-850
116. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97:2880-2886
117. Hickok JT, Roscoe JA, Morrow GR, Ryan JL (2007) A phase II/III randomized, placebo-controlled, double-blind clinical trial of ginger (Zingiber officinale) for nausea caused by chemotherapy for cancer: a currently accruing URCC CCOP cancer control study. Support Cancer Ther 4:247-250. doi:10.3816/SCT.2007.n.022
118. Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY (2010) A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol 40:294-301. doi:10.1093/jjco/hyp169
119. Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L (2014) Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer 22:979-987. doi:10.1007/s00520-013-2043-9
120. Hughson AV, Cooper AF, McArdle CS, Smith DC (1986) Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J (Clin Res Ed) 293:1268-1271
121. Hulstaert F, Van Belle S, Bleiberg H, Canon JL, Dewitte M, Buyse M, De Keyser P, Westelinck KJ (1994) Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 12:2439-2446
122. Ibrahim EM, Al-Idrissi HY, Ibrahim A, Absood G, Al-Dossary E, Al-Jammaa A, Al-Ethan S, Eliopoulos A (1986) Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 22:283-288
123. Ioannidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 18:3409-3422
124. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
125. Iversen LL (2008) The science of marijuana, 2nd edn. Oxford University Press, New York
126. Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14:757-766
127. Jang G, Song HH, Park KU, Kim HS, Choi DR, Kwon JH, Kim HY, Han B, Kim JH, Jung JY, Kim HJ, Zang DY (2013) A phase II study to evaluate the efficacy of ramosetron, aprepitant, and dexamethasone in preventing cisplatin-induced nausea and vomiting in chemotherapy-naïve cancer patients. Cancer Res Treat 45:172-177. doi:10.4143/crt.2013.45.3.172
128. Janinis J, Giannakakis T, Athanasiades A, Fountzilas G, Bafaloukos D, Kosmidis P, Nikolaides K, Pavlidis N, Skarlos D (2000) A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study. Tumori 86:37-41
129. Jin Y, Wu X, Guan Y, Gu D, Shen Y, Xu Z, Wei X, Chen J (2012) Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer 20:1815-1822. doi:10.1007/s00520-011-1280-z
130. Johansson R, Kilkku P, Groenroos M (1982) A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 9(Suppl B):25-33
131. Johansson S, Steineck G, Hursti T, Fredrikson M, Fürst CJ, Peterson C (1991) Effects of ondansetron on chemotherapyinduced acute and delayed emesis - a pilot study. Acta Oncol 30:649-651
132. Jones SE, Durant JR, Greco FA, Robertone A (1982) A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 9:45-48
133. Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, Sikora K, Carney DN, Cunningham D (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483-487
134. Jordan K, Kasper C, Schmoll HJ (2005) Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 41:199-205
135. Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197-202
136. Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro MS, Thürlimann B (1994) Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 5:253-258
137. Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, Morrow GR (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172-179. doi:10.1016/j.ejphar.2013.09.071
138. Khoo KS, Ang PT, Soh LT, Au E (1993) Use of oral and intravenous ondansetron in patients treated with cisplatin. Ann Acad Med Singapore 22:901-904
139. Kleisbauer JP, García-Girón C, Antimi M, Azevedo MC, Balmes H, Massuti-Sureda B, Contu A, Luque A, Pellier P (1998) Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 9:387-392
140. Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA (1979) Delta 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 2:338-340
141. Kornblith AB, Herndon JE 2nd, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, Mertz M, Payne D, Jane Massie M, Holland JF, Wingate P, Norton L, Holland JC (2003) Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 98:679-689
142. Kumagai H, Kusaba H, Okumura Y, Komoda M, Nakano M, Tamura S, Uchida M, Nagata K, Arita S, Ariyama H, Takaishi S, Akashi K, Baba E (2014) Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. Asian Pac J Cancer Prev 15:461-465
143. Kvale G, Hugdahl K, Asbjørnsen A, Rosengren B, Lote K, Nordby H (1991) Anticipatory nausea and vomiting in cancer patients. J Consult Clin Psychol 59:894-898
144. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Salva K, Wiernik PH, Holroyde CP, Hammill S et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6:352-359
145. Laszlo J, Clark RA, Hanson DC, Tyson L, Crumpler L, Gralla R (1985) Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. J Clin Oncol 3:864-869
146. Leibundgut U, Lancranjan I (1987) First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1:1198
147. Levine ME, Gillis MG, Koch SY, Voss AC, Stern RM, Koch KL (2008) Protein and ginger for the treatment of chemotherapy-induced delayed nausea. J Altern Complement Med 14:545-551. doi:10.1089/acm.2007.0817
148. Levitt M (1982) Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 9:49-53
149. Limebeer CL, Parker LA, Fletcher PJ (2004) 5,7-Dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping but not conditioned taste avoidance in rats. Behav Neurosci 118:1391-1399
150. Limebeer CL, Hall G, Parker LA (2006) Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88:398-403. doi:10.1016/j.physbeh.2006.04.014
151. Limebeer CL, Krohn JP, Cross-Mellor S, Litt DE, Ossenkopp KP, Parker LA (2008) Exposure to a context previously associated with nausea elicits conditioned gaping in rats: a model of anticipatory nausea. Behav Brain Res 187:33-40
152. Limebeer CL, Rock EM, Mechoulam R, Parker LA (2012) The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol 167:1126-1136
153. Limebeer CL, Abdullah RA, Rock EM, Imhof E, Wang K, Lichtman AH, Parker LA (2014) Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. Psychopharmacology 231:603-612. doi:10.1007/s00213-013-3282-7
154. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 106:20270-20275. doi:10.1073/pnas.0909411106
155. Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M (2011) Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 19:1159-1164. doi:10.1007/s00520- 010-0930-x
156. Lorusso V, Giampaglia M, Petrucelli L, Saracino V, Perrone T, Gnoni A (2012) Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. Support Care Cancer 20:3241-3246. doi:10.1007/s00520-012-1469-9
157. Lucas VS Jr, Laszlo J (1980) Delta 9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243:1241-1243
158. Lumb AB (1993) Mechanism of antiemetic effect of ginger. Anaesthesia 48:1118
159. Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M, Imamura F, Katakami N, Hida T, Takeo S, PALO Japanese Cooperative Study Group (2009) A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol 20:1860-1866. doi:10.1093/annonc/mdp195
160. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170-175
161. Manusirivithaya S, Sripramote M, Tangjitgamol S, Sheanakul C, Leelahakorn S, Thavaramara T, Tangcharoenpanich K (2004) Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 14:1063-1069
162. Markman M (2002) Progress in preventing chemotherapy-induced nausea and vomiting. Clevel Clin J Med 69:609-617
163. Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM (2003) Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395-1401
164. Maru A, Gangadharan VP, Desai CJ, Mohapatra RK, Carides AD (2013) A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Indian J Cancer 50:285-291. doi:10.4103/0019-509X.123580
165. Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G (2009) Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and nonelderly patient response. Crit Rev Oncol Hematol 70:83-91. doi:10.1016/j.critrevonc.2008.07.002
166. Massaro AM, Lenz KL (2005) Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 39:77-85
167. Matteson S, Roscoe JR, Hickok J, Morrow GR (2002) The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 186:S239-S243
168. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6:243-246
169. Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121:35-43
170. Mechoulam R, Shani A, Edery H, Grunfeld Y (1970) Chemical basis of hashish activity. Science 169:611-612
171. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533-543. doi:10.1185/030079907X167525
172. Merkus FW (1971) Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature 232:579-580
173. Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497-499
174. Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H (2013) The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:2575-2581. doi:10.1007/s00520-013-1835-2
175. Molassiotis A, Nguyen AM, Rittenberg CN, Makalinao A, Carides A (2013) Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy. Future Oncol 9:1443-1450. doi:10.2217/fon.13.155
176. Montgomery GH, Tomoyasu N, Bovbjerg DH, Andrykowski MA, Currie VE, Jacobsen PB, Redd WH (1998) Patients' pretreatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea. Ann Behav Med 20:104-109
177. Moreno J, Sahade M, del Giglio A (2005) Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 13:850-853
178. Morrow GR (1982) Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68:585-588
179. Morrow GR (1984) Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 2:1170-1176
180. Morrow GR (1992) Behavioural factors influencing the development and expression of chemotherapy induced side effects. Br J Cancer Suppl 19:S54-S60
181. Morrow GR, Hickok JT (1993) Behavioral treatment of chemotherapy-induced nausea and vomiting. Oncology (Williston Park) 7:83-89
182. Morrow GR, Rosenthal SN (1996) Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53(Suppl 1):4-7
183. Morrow GR, Lindke JL, Black PM (1991) Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage 6:215-223
184. Morrow GR, Ashbury R, Hammon S, Dobkin P, Caruso L, Pandya K, Rosenthal S (1992) Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists. Health Psychol 11:250-256
185. Morrow GR, Roscoe JA, Hynes HE, Flynn PJ, Pierce HI, Burish T (1998a) Progress in reducing anticipatory nausea and vomiting: a study of community practice. Support Care Cancer 6:46-50
186. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ (1998b) Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 6:244-247
187. Morrow GR, Hickok JT, Andrews PLR, Stern RM (2002a) Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? Psychophysiology 39:491-495
188. Morrow GR, Roscoe JA, Hickok JT, Andrews PLR, Matteson S (2002b) Nausea and emesis: evidence for a biobehavioral perspective. Support Care Cancer 10:96-105
189. Münstedt K, Müller H, Blauth-Eckmeyer E, Stenger K, Zygmunt M, Vahrson H (1999) Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Br J Cancer 79:637-639
190. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 17:205-209. doi:10.1007/s00520- 008-0510-5
191. Mustian KM, Devine K, Ryan JL, Janelsins MC et al (2011) Treatment of nausea and vomiting during chemotherapy. US Oncol Hematol 7:91-97
192. Nakayama Y, Ito Y, Tanabe M, Takahashi S, Hatake K (2013) A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study. Breast Cancer [Epub ahead of print]
193. Navari RM (2012) Treatment of chemotherapy-induced nausea. Commun Oncol 9:20-26
194. Navari R (2013a) The current status of the use of palonosetron. Expert Opin Pharmacother 14:1281-1284. doi:10.1517/14656566.2013.799141
195. Navari RM (2013b) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249-262
196. Nerenz DR, Leventhal H, Love RR, Ringler KE (1984) Psychological aspects of cancer chemotherapy. Appl Psychol 33:521-529
197. Nerenz DR, Leventhal H, Easterling DV, Love RR (1986) Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J Clin Oncol 4:224-233
198. Nesse RM, Carli T, Curtis GC, Kleinman PD (1980) Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42:33-36
199. Ng WL, Della-Fiorentina SA (2010) The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. Eur J Cancer Care (Engl) 19:403-407. doi:10.1111/j.1365-2354.2009.01068.x
200. Niamatali C, Fallon SD, Egan EL (1984) Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis. Ir Med J 77:276-277
201. Niiranen A, Mattson K (1985) A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8:336-340
202. Niiranen A, Mattson K (1987) Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 10:325-329
203. O'Shaughnessy WB (1843) On the preparations of the Indian hemp, or Gunjah: Cannabis indica; their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci 5:363-369
204. Oechsle K, Müller MR, Hartmann JT, Kanz L, Bokemeyer C (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 29:557-561
205. Oettle H, Riess H (2001) Treatment of chemotherapy-induced nausea and vomiting. J Cancer Res Clin Oncol 127:340-345
206. Oliere S, Joliette-Riopel A, Potvin S, Jutras-Aswad D (2013) Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry 4:109. doi:10.3389/fpsyt.2013.00109
207. Orr LE, McKernan JF (1981) Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 21:76S-80S
208. Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140:1431-1433
209. Oyama K, Fushida S, Kaji M, Takeda T, Kinami S, Hirono Y, Yoshimoto K, Yabushita K, Hirosawa H, Takai Y, Nakano T, Kimura H, Yasui T, Tsuneda A, Tsukada T, Kinoshita J, Fujimura T, Ohta T (2013) Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. J Gastroenterol 48:1234-1241. doi:10.1007/s00535-012-0746-1
210. Pace JC (1987) Oral ingestion of encapsulated ginger and reported self-care actions for the relief of chemotherapy-associated nausea and vomiting. Diss Abstr Int (Sci) 47:3297
211. Palatty PL, Haniadka R, Valder B, Arora R, Baliga MS (2013) Ginger in the prevention of nausea and vomiting: a review. Crit Rev Food Sci Nutr 53:659-669. doi:10.1080/10408398.2011.553751
212. Panahi Y, Saadat A, Sahebkar A, Hashemian F, Taghikhani M, Abolhasani E (2012) Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr Cancer Ther 11:204-211. doi:10.1177/1534735411433201
213. Parikh PM, Shah SR, Shah SC, Sheth V, Patel RA, Shah KC, Jain PK (1996) Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. Indian J Cancer 33:17-20
214. Parker LA (2014) Conditioned flavor avoidance and conditioned gaping: rat models of conditioned nausea. Eur J Pharmacol 722:122-133. doi:10.1016/j. ejphar.2013.09.070
215. Parker LA, Kemp SW (2001) Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). NeuroReport 12:749-751
216. Parker LA, Limebeer CL (2006) Conditioned gaping in rats: a selective measure of nausea. Auton Neurosci 129:36-41
217. Parker LA, Hills K, Jensen K (1984) Behavioral CRs elicited by lithium- or an amphetamine-paired contextual test chamber. Anim Learn Behav 12:307-315
218. Parker RI, Prakash D, Mahan RA, Giugliano DM, Atlas MP (2001) Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. J Pediatr Hematol Oncol 23:578-581
219. Parker LA, Kwiatdowska M, Mechoulam R (2006) Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87:66-71
220. Parker LA, Rock EM, Limebeer CL (2011) Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 163:1411-1422. doi:10.1111/j.1476-5381.2010. 01176.x
221. Penfield W, Faulk ME (1955) The insula: further observations on its function. Brain 78:445
222. Perez EA (1998) Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Cancer J Sci Am 4:72-77
223. Perez J (2006) Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42:495-503. doi:10.1358/dot.2006.42.8.1021517
224. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397-411. doi:10.1111/j.1476-5381. 2008.00048.x
225. Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK (2007) The psychoactive plant cannabinoid, delta9-tetrahydrocannabinol, is antagonized by delta8- and delta9- tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150:586-594. doi:10.1038/sj.bjp.0707124
226. Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JW, Guchelaar HJ (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33:33-43. doi:10.1007/s11096-010-9454-1
227. Pieters RC, Vermorken JB, Gall HE, Nauta JJ, van Loenen AC, van Groeningen CJ, van Rijswijk RE, Brenninkmeijer JH, Pinedo HM (1993) A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy. Oncology 50:316-322
228. Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 56:234-238
229. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
230. Pomeroy M, Fennelly JJ, Towers M (1986) Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17:285-288
231. Poster DS, Penta JS, Bruno S, Macdonald JS (1981) Delta 9-tetrahydrocannabinol in clinical oncology. JAMA 245:2047-2051
232. Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P (2006) Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. J Med Assoc Thai 89(Suppl 4):S29-S36
233. Priestman TJ, Priestman SG (1984) An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol 35:265-266
234. Qian QH, Yue W, Chen WH, Yang ZH, Liu ZT, Wang YX (2010) Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J (Engl) 123:478-484
235. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423-431. doi:10.1007/s00520-009-0680-9
236. Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde MP, Beauduin M, Piccart M (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11:1384-1390
237. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196:389-395. doi:10.1007/s00213-007-0970-1
238. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620-2634. doi:10.1111/j.1476-5381.2011.01621.x
239. Rock EM, Kopstick RL, Limebeer CL, Parker LA (2013a) Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 170:641-648. doi:10.1111/bph. 12316
240. Rock EM, Sticht MA, Duncan M, Stott C, Parker LA (2013b) Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9)-tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol 170:671-678. doi:10.1111/bph.12322
241. Rock EM, Limebeer CL, Navaratnuam R, Sticht MA, Bonner N, Engeland, K, Downey R, Morris H, Parker LA (2014) A comparison of treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology [Epub ahead of print]
242. Rodriguez M, Lopez M, Symonds M, Hall G (2000) Lithium-induced context aversion in rats as a model of anticipatory nausea in humans. Physiol Behav 71:571-579
243. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
244. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243. doi:10.1093/annonc/mdq194
245. Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32:101-106. doi:10.1200/JCO.2013.51.4547
246. Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113-121
247. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I (2011) Anticipatory nausea and vomiting. Support Care Cancer 19:1533-1538
248. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR (2012) Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20:1479-1489. doi:10.1007/s00520-011-1236-3
249. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124. doi:10.1016/S1470-2045(08)70313-9
250. Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067-1073. doi:10.1093/annonc/mds541
251. Sallen SE, Zinberg NE, Frei E 3rd (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293:795-797
252. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006
253. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Márquez H, Villasis-Keever MA, Del Angel VW, Díaz FC, López-Aguilar E (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601-606. doi:10.1016/j.arcmed.2008.04.007
254. Seynaeve C, De Mulder PH, Verweij J, Gralla RJ (1991) Controlling cancer chemotherapy-induced emesis. An update. Pharm Weekbl Sci 13:189-197
255. Sharkey KA, Darmani NA, Parker LA (2014) Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol 722:134-146. doi:10.1016/j.ejphar.2013.09.068
256. Sharma SS, Kochupillai V, Gupta SK, Seth SD, Gupta YK (1997) Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. J Ethnopharmacol 57:93-96
257. Sontakke S, Thawani V, Naik MS (2003) Ginger as an anti-emetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Ind J Pharmacol 35:32-36
258. Sorbe B (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Ann Oncol 4(Suppl 3):39-42
259. Sorbe BG (1994) Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Semin Oncol 21:S20-S26
260. Sorbe BG, Högberg T, Glimelius B, Schmidt M, Wernstedt L, Andersson H, Hansen O, Sørensen BT, Räisänen I (1995) Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group. Anticancer Drugs 6(Suppl 1):31-36
261. Sorbe BG, Berglind AM, Andersson H, Boman K, Högberg T, Hallgren M, Schmidt M (1998) A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 83:1022-1032
262. Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64:219-224
263. Stewart DJ (1990) Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 68:304-313
264. Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, Parker LA (2012) Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol 165:2425-2435. doi:10.1111/j.1476-5381.2011.01407.x
265. Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ (1993) Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci 28:177-181
266. Stockhorst U, Wiener JA, Klosterhalfen S, Klosterhalfen W, Aul C, Steingruber HJ (1998) Effects of overshadowing on conditioned nausea in cancer patients: an experimental study. Physiol Behav 64:743-753
267. Stockhorst U, Steingrueber HJ, Enck P, Klosterhalfen S (2006) Pavlovian conditioning of nausea and vomiting. Auton Neurosci Basic Clin 129:50-57
268. Stuart-Harris RC, Mooney CA, Smith IE (1983) Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional antiemetic therapy. Clin Oncol 9:143-146
269. Suzuki T, Sugimoto M, Koyama H, Mashimo T, Uchida I (2004) Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in Xenopus oocytes. Anesthesiology 101:660-665
270. Sweet DL (1980) Marijuana for drug-induced nausea and vomiting. JAMA 243:1265. doi:10.1001/jama.1980.03300380045025
271. Sweet DL, Miller NJ, Weddington W, Senay E, Sushelsky L (1981) Delta 9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21:70S-75S
272. Symonds M, Hall G (2002) Postinjection suppression of drinking is modified by the presence of conditioned contextual cues: implications for both anticipatory and posttreatment nausea in humans. Anim Learn Behav 30:355-362
273. Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K (2010) Multicenter, phase II, placebo-controlled, doubleblind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101:2455-2461. doi:10.1111/j.1349-7006.2010.01689.x
274. Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859-865. doi:10.1038/bjc.2013.400
275. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917-926
276. Torii Y, Saito H, Matsuki N (1991) 5-Hydroxytryptamine is emetogenic in the house musk shrew, Suncus murinus. Naunyn-Schmiedeberg's Arch Pharmacol 344:564-567
277. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16-21. doi:10.1136/bmj.323.7303.16
278. Travers JB, Norgren R (1986) Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci 100:544-555
279. Tsuji D, Kim YI, Taku K, Nakagaki S, Ikematsu Y, Tsubota H, Maeda M, Hashimoto N, Kimura M, Daimon T (2012) Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a doubleblind, randomized, non-inferiority trial. Support Care Cancer 20:1057-1064. doi:10.1007/s00520-011-1185-x
280. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, Kimura M, Taguchi T, Yoshida T, Nagao J, Sakuma Y, Toth G (2009) Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial. Int J Clin Oncol 14:337-343. doi:10.1007/s10147-008-0874-z
281. Tuerke KJ, Limebeer CL, Fletcher PJ, Parker LA (2012) Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT3 receptor in the posterior and anterior insular cortex. J Neurosci 32:13709-13717
282. Tyc VL, Mulhern RK, Bieberich AA (1997) Anticipatory nausea and vomiting in pediatric cancer patients: an analysis of conditioning and coping variables. J Dev Behav Pediatr 18:27-33
283. Uchida M, Ikesue H, Kato K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Egashira N, Akashi K, Oishi R (2013) Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm 70:343-349. doi:10.2146/ajhp120363
284. Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG (1984) Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology 150:598-599
285. van Komen RW, Redd WH (1985) Personality factors associated with anticipatory nausea/vomiting in patients receiving cancer chemotherapy. Health Psychol 4:189-202
286. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of ferret. Gastroenterology 121:767-774
287. Villalon A, Chan V (2004) Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer 12:58-63
288. Vinciguerra V, Moore T, Brennan E (1988) Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State J Med 88:525-527
289. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 9(Suppl B):39-44
290. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit RD, Carides AD, Taylor A, Evans JK, Horgan KJ (2005a) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278-1285
291. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005b) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830
292. Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-ofcare antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19:807-813. doi:10.1007/s00520-010-0899-5
293. Watson M, McCarron J, Law M (1992) Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. Br J Cancer 66:862-866
294. Watson M, Meyer L, Thomson A, Osofsky S (1998) Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 34:831-837
295. Watters J, Riley M, Pedley I, Whitehead A, Overend M, Goss I, Allgar V (2001) The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting. Clin Oncol (R Coll Radiol) 13:422-426
296. White L, Daly SA, McKenna CJ, Zhestkova N, Leal C, Breatnach F, Smelhaus V, Hung IJ, Kowalczyk J, Ninane J, Mitchell T, Haigh C (2000) A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 17:445-455
297. Yekta ZP, Ebrahimi SM, Hosseini M, Nasrabadi AN, Sedighi S, Surmaghi MH, Madani H (2012) Iran J Nurs Midwifery Res 17:325-329
298. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113:529-535. doi:10.1007/s10549-008-9957-9
299. Zachariae R, Paulsen K, Mehlsen M, Jensen AB, Johansson A, von der Maase H (2007) Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity. Ann Behav Med 33:69-79
300. Zaglama NE, Rosenblum SL, Sartiano GP, Brady M, Gonzalez MF, Valdivieso JG (1986) Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 43:27-32
301. Zick SM, Ruffin MT, Lee J, Normolle DP, Siden R, Alrawi S, Brenner DE (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563-572. doi:10.1007/s00520-008-0528-8